Influenza vaccine effectiveness in children: a retrospective study on eight post-pandemic seasons with trivalent inactivated vaccine.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
received:
19
03
2020
accepted:
24
03
2020
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
30
3
2021
Statut:
epublish
Résumé
The global burden of disease attributable to seasonal influenza virus in children is difficult to quantify. Children with chronic medical conditions and healthy children may experience severe or fatal complications. Aim of the study was to estimate the influenza vaccine effectiveness (VE) in a cohort of outpatient children. From 2010 to 2018, a Pediatrician of Parma from the InfluNet network of Emilia-Romagna Region, performed nasal/throat swabs on every child with Influenza-like illness at least 14 days from the vaccination with trivalent vaccine. VE estimates against influenza season, virus type and subtype and age group were evaluated using a test-negative design. 2,480 swabs were performed. The 57.6% of the analyzed swabs were positive for influenza viruses. Type A (57%) and type B viruses (43%) co-circulated. The 37.1% of type A viruses belonged to subtype A(H3N2), 19.4% to subtype A(H1N1)pdm09. The subtype A(H3N2) was prevalent among children up to 23 months (42.4%) while the type B in the 2-4 (40.7%) and 5-16 year old age groups (49.4%). Overall, 19.9% of the children were vaccinated. The highest prevalence of vaccinated subjects was found in children aged 5-16 (30.5%). The VE against subtype A(H1N1)pdm09 was 63% (95%CI 42.6-76.0), against type B 27.5% (95%CI 7.9-42.9) and against subtype A(H3N2) -14.3% (95%CI - 46.0-10.7). Our findings represent a useful contribution to the ongoing debate about the appropriateness of including influenza vaccination for healthy children, 6 months and older, in the updating National Vaccine Prevention Plan (PNPV).
Sections du résumé
BACKGROUND AND AIM OF THE WORK
The global burden of disease attributable to seasonal influenza virus in children is difficult to quantify. Children with chronic medical conditions and healthy children may experience severe or fatal complications. Aim of the study was to estimate the influenza vaccine effectiveness (VE) in a cohort of outpatient children.
METHODS
From 2010 to 2018, a Pediatrician of Parma from the InfluNet network of Emilia-Romagna Region, performed nasal/throat swabs on every child with Influenza-like illness at least 14 days from the vaccination with trivalent vaccine. VE estimates against influenza season, virus type and subtype and age group were evaluated using a test-negative design.
RESULTS
2,480 swabs were performed. The 57.6% of the analyzed swabs were positive for influenza viruses. Type A (57%) and type B viruses (43%) co-circulated. The 37.1% of type A viruses belonged to subtype A(H3N2), 19.4% to subtype A(H1N1)pdm09. The subtype A(H3N2) was prevalent among children up to 23 months (42.4%) while the type B in the 2-4 (40.7%) and 5-16 year old age groups (49.4%). Overall, 19.9% of the children were vaccinated. The highest prevalence of vaccinated subjects was found in children aged 5-16 (30.5%). The VE against subtype A(H1N1)pdm09 was 63% (95%CI 42.6-76.0), against type B 27.5% (95%CI 7.9-42.9) and against subtype A(H3N2) -14.3% (95%CI - 46.0-10.7).
CONCLUSIONS
Our findings represent a useful contribution to the ongoing debate about the appropriateness of including influenza vaccination for healthy children, 6 months and older, in the updating National Vaccine Prevention Plan (PNPV).
Identifiants
pubmed: 32275269
doi: 10.23750/abm.v91i3-S.9424
pmc: PMC7975907
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-70Références
Cochrane Database Syst Rev. 2018 Feb 01;2:CD004879
pubmed: 29388195
Vaccine. 2016 Jun 8;34(27):3102-3108
pubmed: 27154392
Zoonoses Public Health. 2018 Feb;65(1):114-123
pubmed: 28791803
Vaccine. 2010 Oct 28;28(46):7381-8
pubmed: 20851086
Eur J Public Health. 2018 Jun 1;28(3):490-495
pubmed: 29293996
MMWR Recomm Rep. 2019 Aug 23;68(3):1-21
pubmed: 31441906
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
Immunotherapy. 2020 Feb;12(2):105-110
pubmed: 32046555
Vaccine. 2020 Jan 10;38(2):158-164
pubmed: 31648914
Pediatrics. 2018 Oct;142(4):
pubmed: 30177511
Euro Surveill. 2019 Jan;24(5):
pubmed: 30722814
Acta Biomed. 2020 Apr 10;91(3-S):77-84
pubmed: 32275271
N Engl J Med. 2006 Jul 6;355(1):31-40
pubmed: 16822994
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
BMC Infect Dis. 2019 Nov 21;19(1):990
pubmed: 31752738
Hum Vaccin Immunother. 2012 Jan;8(1):17-20
pubmed: 22252002
Front Pediatr. 2019 Jul 30;7:317
pubmed: 31417886
Pediatr Infect Dis J. 2003 Oct;22(10 Suppl):S207-10
pubmed: 14551476
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185
pubmed: 29447141
Expert Rev Vaccines. 2019 Jun;18(6):615-628
pubmed: 31116070
Acta Biomed. 2019 Sep 13;90(9-S):35-44
pubmed: 31517888
Vaccine. 2013 Jun 26;31(30):3104-9
pubmed: 23624093
Ann Ig. 2013 Sep-Oct;25(5):427-33
pubmed: 24048181
Vaccine. 2020 Jan 16;38(3):489-497
pubmed: 31685296
Euro Surveill. 2008 Oct 23;13(43):
pubmed: 18947520
Expert Rev Vaccines. 2019 Nov;18(11):1201-1209
pubmed: 31674847
Acta Biomed. 2019 Sep 13;90(9-S):21-27
pubmed: 31517886
Pediatrics. 2019 Oct;144(4):
pubmed: 31477606
Euro Surveill. 2019 Feb;24(8):
pubmed: 30808440